Treatment Patterns and Clinical Outcomes in Unresectable Stage III EGFR-Mutated Non-Small Cell Lung Cancer in China

Key Points

• To examine treatment patterns and clinical outcomes for patients with unresectable stage III EGFR-mutated non-small cell lung cancer in China.
• Analyzed real-world data from patients with unresectable stage III NSCLC
• Compared first-generation EGFR-TKIs with chemoradiotherapy
• Measured outcomes like real-world progression-free survival (rwPFS) and real-world time to next treatment (rwTTNTD)
• First-generation EGFR-TKIs showed numerically longer rwPFS compared to chemoradiotherapy alone
• Patients on first-generation EGFR-TKIs had longer rwTTNTD than those receiving only chemoradiotherapy
• Persistent unmet need to improve overall survival rates in this patient group